Abstract
Background
Bevacizumab is the first angiogenesis inhibitor to be approved for metastatic colorectal cancer. Unfortunately, bevacizumab treatment has been associated with a variety of complications including haemorrhage, poor wound healing and gastrointestinal perforation. Late anastomotic breakdown related to bevacizumab therapy however has rarely been described.
Case report
Here, we present the case of a 56-year-old woman who had a bevacizumab-related anastomotic breakdown 17 months following her primary anastomosis. She initially underwent an emergency Hartmann’s procedure and two further laparotomies for significant intra-abdominal haemorrhage. Despite the best efforts of the surgical and intensive care teams, ultimately, the patient passed away.
Discussion
There is a small but growing body of literature relating to bevacizumab use and late anastomotic breakdown. It would seem prudent to take extra caution when using bevacizumab in those patients with previous pelvic irradiation, who have a rectal site of anastomosis or have experienced a previous anastomotic leak.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Liu SV, Gollard R, Iqbal S (2012) Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab. J Clin Pharm Ther 37(5):607–609
Collins D, Ridgway PF, Winter DC, Fennelly D, Evoy D (2009) Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy. Eur J Surg Oncol 35(4):444–446
August DA, Serrano D, Poplin E (2008) “Spontaneous,” delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 97(2):180–185
Ley EJ, Vukasin P, Kaiser AM, Ault G, Beart RW Jr (2007) Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin). Dis Colon rectum 50(6):930
Abbrederis K, Kremer M, Schuhmacher C (2008) Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery. Chirurg 79(4):351–355
Takada S, Hoshino Y, Ito H, Masugi Y, Terauchi T, Endo K et al (2015) Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. Jpn J Clin Oncol 45(3):286–290
Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26(1):76–82
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111
Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U (2009) Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Investig New Drugs 27(2):184–187
Sorensen LT (2006) Effect of lifestyle, gender and age on collagen formation and degradation. Hernia 10(6):456–461
Bege T, Lelong B, Viret F, Turrini O, Guiramand J, Topart D et al (2009) Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients. Ann Surg Oncol 16(4):856–860
Adenis A, Vanseymortier L, Foissey D, Colombel JF (2007) Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. Gut 56(5):734
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15–18
Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69(Suppl 3):25–33
Hurwitz H, Kabbinavar F (2005) Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 69(Suppl 3):17–24
Neufeld G, Kessler O, Vadasz Z, Gluzman-Poltorak Z (2001) The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors. Surg Oncol Clin N Am 10(2):339–356 ix
Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M (2006) Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64(5):1295–1298
Akkouche A, Sideris L, Leblanc G, Leclerc YE, Vafiadis P, Dube P (2008) Complications after colorectal anastomosis in a patient with metastatic rectal cancer treated with systemic chemotherapy and bevacizumab. Canadian journal of surgery Journal canadien de chirurgie 51(3):E52–E53
Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22(10):1198
Wolf I, Urban D, Pfeffer R, Catane R, Aderka D (2007) High incidence of fistula formation during bevacizumab treatment in rectal cancer patients. Acta Oncol 46(4):550–553
Borzomati D, Nappo G, Valeri S, Vincenzi B, Ripetti V, Coppola R (2013) Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updat Surg 65(2):121–124
Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G (2007) Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2(6):571–573
Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559–568
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326–5334
Rullier E, Laurent C, Garrelon JL, Michel P, Saric J, Parneix M (1998) Risk factors for anastomotic leakage after resection of rectal cancer. Br J Surg 85(3):355–358
Buchs NC, Gervaz P, Secic M, Bucher P, Mugnier-Konrad B, Morel P (2008) Incidence, consequences, and risk factors for anastomotic dehiscence after colorectal surgery: a prospective monocentric study. Int J Color Dis 23(3):265–270
Heinzerling JH, Huerta S (2006) Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63(5):334–337
Tibbs MK (1997) Wound healing following radiation therapy: a review. Radiother Oncol 42(2):99–106
Nakamura H, Yokoyama Y, Uehara K, Kokuryo T, Yamaguchi J, Tsuzuki T et al (2016) The effects of bevacizumab on intestinal anastomotic healing in rabbits. Surg Today
Power N, Atri M, Ryan S, Haddad R, Smith A (2007) CT assessment of anastomotic bowel leak. Clin Radiol 62(1):37–42
Funding
No funding was received for this case-based review from any party.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
O’Hare, T., McDermott, R. & Hannon, R. Late anastomotic breakdown with bevacizumab in colorectal cancers, a case-based review. Ir J Med Sci 187, 333–336 (2018). https://doi.org/10.1007/s11845-017-1676-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-017-1676-y